LOBEFARO, RICCARDO
 Distribuzione geografica
Continente #
NA - Nord America 208
EU - Europa 181
AS - Asia 47
SA - Sud America 3
Continente sconosciuto - Info sul continente non disponibili 1
Totale 440
Nazione #
US - Stati Uniti d'America 200
SE - Svezia 50
IT - Italia 43
GB - Regno Unito 33
CN - Cina 29
IE - Irlanda 20
FR - Francia 9
BE - Belgio 8
CA - Canada 8
DK - Danimarca 7
ID - Indonesia 6
HK - Hong Kong 4
JP - Giappone 4
UA - Ucraina 4
BR - Brasile 3
DE - Germania 3
IN - India 2
NL - Olanda 2
AP - ???statistics.table.value.countryCode.AP??? 1
CH - Svizzera 1
KR - Corea 1
RU - Federazione Russa 1
UZ - Uzbekistan 1
Totale 440
Città #
Chandler 80
Southend 22
Dublin 20
Princeton 13
Wilmington 12
Fairfield 11
Milan 9
Brussels 8
Ann Arbor 6
Ashburn 6
Cambridge 6
Phoenix 6
Dearborn 5
Rho 5
Seattle 5
Woodbridge 5
Beijing 4
Houston 4
Toronto 4
Nanjing 3
Tokyo 3
Casorate Primo 2
Central 2
Delhi 2
Des Moines 2
Fornovo San Giovanni 2
Grafing 2
Jesolo 2
Jinan 2
London 2
Manchester 2
Monza 2
Nanchang 2
Ottawa 2
Pontefract 2
San Diego 2
Shenyang 2
São Paulo 2
Taizhou 2
Tianjin 2
Amsterdam 1
Central District 1
Changsha 1
Ferrara di Monte Baldo 1
Haikou 1
Medford 1
Montréal 1
North Bergen 1
Orta di Atella 1
Redwood City 1
Rochester 1
Rotterdam 1
Seoul 1
Sha Tin Wai 1
Vancouver 1
Totale 290
Nome #
The landscape of actionable gene fusions in colorectal cancer 100
“Systemic strategy at the patient’s service”: A congress report on supportive care in oncology 75
Anti-EGFR Therapy in Metastatic Small Bowel Adenocarcinoma : Myth or Reality? 67
Capecitabine and Temozolomide versus FOLFIRI in RAS-Mutated, MGMT-Methylated Metastatic Colorectal Cancer 59
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology 37
PillarX: A Microfluidic Device to Profile Circulating Tumor Cell Clusters Based on Geometry, Deformability, and Epithelial State 30
The pan-immune-inflammation-value predicts the survival of patients with human epidermal growth factor receptor 2 (Her2)—positive advanced breast cancer treated with first-line taxane-trastuzumab-pertuzumab 24
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program 23
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers 19
Targeting lipid metabolism is an emerging strategy to enhance the efficacy of anti-HER2 therapies in HER2-positive breast cancer 18
Case Report: Prolonged clinical benefit with sequential trastuzumab-containing treatments in a patient with advanced extramammary Paget disease of the groin 15
Exceptional tumour responses to fasting-mimicking diet combined with standard anticancer therapies: A sub-analysis of the NCT03340935 trial 9
Hormone Receptor Loss in Breast Cancer: Molecular Mechanisms, Clinical Settings, and Therapeutic Implications 5
Totale 481
Categoria #
all - tutte 1114
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 1114


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/20182 0000 00 00 0002
2018/20199 3110 01 20 1000
2019/202067 2000 12 40 331447
2020/202160 5774 37 47 10222
2021/202281 5242 23 07 813134
2022/2023261 26262226 2151 627 258230
Totale 481